Flagship Harbor Advisors LLC Has $5.11 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Flagship Harbor Advisors LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,189 shares of the company's stock after selling 353 shares during the period. Flagship Harbor Advisors LLC's holdings in Eli Lilly and Company were worth $5,112,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $43,000. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth $48,000. Highline Wealth Partners LLC grew its position in Eli Lilly and Company by 53.3% during the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock worth $57,000 after purchasing an additional 24 shares during the last quarter. Capital A Wealth Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at $63,000. Finally, Bellwether Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $66,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY stock traded up $8.33 on Tuesday, reaching $778.97. 2,773,370 shares of the company were exchanged, compared to its average volume of 3,666,228. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The stock's fifty day moving average price is $780.81 and its 200 day moving average price is $800.36. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm has a market capitalization of $738.26 billion, a PE ratio of 63.38, a PEG ratio of 1.11 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the company posted $2.58 earnings per share. The company's revenue for the quarter was up 45.2% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's payout ratio is 48.82%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, June 7th. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, UBS Group lowered their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,011.79.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.